Post on 24-Apr-2018
OCTOBER 27 - 28, 2017 | HILTON HABTOOR HOTEL, LEBANON7
THE 2ND CONTINUOUS EDUCATIONFOR ONCOLOGY PRACTITIONERS
OCTOBER 27 - 28, 2017HILTON HABTOOR HOTEL, LEBANON
THE 2ND CONTINUOUSEDUCATION FOR
7
ONCOLOGYPRACTITIONERS
3 CE CREDITS
THE LEBANESE ORDEROF PHARMACISTS
IN COLLABORATION WITH:
OCTOBER 27 - 28, 2017 | HILTON HABTOOR HOTEL, LEBANON7
THE 2ND CONTINUOUS EDUCATIONFOR ONCOLOGY PRACTITIONERS
OCTOBER 27 - 28, 2017 | HILTON HABTOOR HOTEL, LEBANON7
THE 2ND CONTINUOUS EDUCATIONFOR ONCOLOGY PRACTITIONERS
Friday October 27, 2017
13:00 Registration
14:00 - 14:15 Welcoming Note and Introduction Fadi Nasr
14:15 - 14:35 Cancer Patient Support Hani Nassar14:15 - 14:20 BNA Main Achievements: Facts & Figures14:20 - 14:30 Patients Testimonials14:30 - 14:35 Future Projects
14:35 - 15:35 CLLModerators: Souad Maalouf - Daisy Samaha - Tony Yammine - Perla Mousallem
14:35 - 14:55 Chemotherapy Free Era in CLLLecture Sponsored by Abbvie
Colette Hanna
14:55 - 15:05 Nurse Perspective Sahar Attieh15:05 - 15:15 Clinical Pharmacy Perspective Nadine Zaineb15:15 - 15:25 Cytogenetic Perspective Alain Chebly15:25 - 15:35 Internal Medicine Souhail Araa
15:35 - 16:00 Coffee Break
16:00 - 16:30Moderators: Rabih Tamim - Manale DibExploring New Directions in NSCLCSymposium Sponsored by Roche
Fadi El Karak
16:30 - 17:30 Multiple Myeloma
Moderators: Elie Rassy - Warde Semaan - Hala Sacre - Jean Claude KhairallahHadi Ghanem - Arlette Hajjar
16:30 - 16:40 Case Presentation Ahmad Khalil16:40 - 16:50 Nurse Perspective Paula Zoghby16:50 - 17:00 Clinical Pharmacy Perspective Aline Hajj17:00 - 17:10 Cytogenetic Perspective Rima Korban17:10 - 17:20 Rheumatology Perspective Jeanine Mnassa17:20 - 17:30 Oncology Perspective Fadi Nasr
THE LEBANESE ORDEROF PHARMACISTS
1 C.E. Credit
OCTOBER 27 - 28, 2017 | HILTON HABTOOR HOTEL, LEBANON7
THE 2ND CONTINUOUS EDUCATIONFOR ONCOLOGY PRACTITIONERS
OCTOBER 27 - 28, 2017 | HILTON HABTOOR HOTEL, LEBANON7
THE 2ND CONTINUOUS EDUCATIONFOR ONCOLOGY PRACTITIONERS
Saturday October 28, 201708:00 Registration09:00 - 10:00 Breast Cancer
Moderators: Marcel Massoud - Leony Antoun - Pierre Najem - Lamis Araa09:00 - 09:12 Case Presentation Anthony Tarabay09:12 - 09:24 Nurse Perspective Stephanie Kaddoum09:24 - 09:36 Clinical Pharmacy Perspective Aline Saad09:36 - 09:48 Surgeon Perspective Michel Hokayem09:48 - 10:00 Oncology Perspective Marcel Massoud
Moderators: Rita Rizk - Joya Dagher10:00 - 10:30 Kisqali (Ribociclib): Power That Redefines First Line
Symposium Sponsored by NovartisDiscussion: Latife Karam Kirejian
Fadi Nasr
10:30 - 11:00 Coffee Break
Moderators: Zeina Hachem - Janah Madah11:00 - 11:40 The Road Ahead in the Management of HR+ mBC
Patients: Are There Differences Between CDK4/6 Inhibitors?Symposium Sponsored by Pfizer
Georges ChahineFadi Nasr
11:40 - 12:00 Psychology of CancerModerator: Rita Sakr
11:40 - 12:00 Evidence & Methods for Supporting Cancer Patients Toni Sawma
12:00 - 12:15 Advanced Nursing PracticeModerator: Gisele Hajal
12:00 - 12:15 Advanced Nursing Practice in Oncology Rima Sassine Kazan
Moderators: Georges Maalouly - Lynn Abdo12:15 - 13:15 Immunotherapy: Redefining Cancer Treatment:
Pembrolizumab in NSCLC, UC, cHLFadi Nasr
Symposium Sponsored by MSDDiscussion: Randa Choueiri
THE LEBANESE ORDEROF PHARMACISTS
2 C.E. Credits
OCTOBER 27 - 28, 2017 | HILTON HABTOOR HOTEL, LEBANON7
THE 2ND CONTINUOUS EDUCATIONFOR ONCOLOGY PRACTITIONERS
Saturday October 28, 2017
Moderator: Nadine Bou Micheal - Noha Al Hachem13:15 - 13:35 Optimizing Treatment Outcomes in Metastatic Gastric
CancerSymposium Sponsored by Eli Lilly
Marwan Ghosn
13:35 - 14:35 Lunch Break
14:35 - 15:35 Lung CancerModerators: Georges Chahine - May Fakhoury - Rachel Ferekh
14:35 - 14:45 Case Presentation Roland Eid14:45 - 14:55 Nurse Perspective Noura Merhi14:55 - 15:05 Clinical Pharmacy Perspective Hanine Elias15:05 - 15:15 Pulmonary Perspective Ihab Ibrahim15:15 - 15:35 New Treatment in Lung Cancer Georges Chahine
Moderator: Carole Deeb15:35 - 16:05 Biosimilars: Pharmaceutical and Clinical Considerations
Symposium Sponsored by RocheFadi Farhat
16:05 - 16:30 Coffee Break
16:30 - 17:10 Current and Evolving Treatment Landscape for I-O in Head and Neck CancersSymposium Sponsored by BMS
Fadi Nasr
Round Table: Georges Farha - Caroline Jabbour - Tanios Eid - Fares Azouri Clement Khoury - Sami Melki - Rami Saade - Antoine Melkane - Charbel Rameh
17:10 - 18:10 Colorectal CancerModerators: Fadi Nasr - Jinane Razzouk - Yasmine Yared - Joseph Amara
17:10 - 17:20 Case Presentation Evelyne Helou17:20 - 17:30 Nurse Perspective Bernard Badr17:30 - 17:40 Clinical Pharmacy Perspective Carole Deeb17:40 - 17:50 Gastroenterology Perspective Antoine Abi Abboud17:50 - 18:10 New Treatment in Colorectal Cancer Evelyne Helou
THE LEBANESE ORDEROF PHARMACISTS
2 C.E. Credits
OCTOBER 27 - 28, 2017 | HILTON HABTOOR HOTEL, LEBANON7
THE 2ND CONTINUOUS EDUCATIONFOR ONCOLOGY PRACTITIONERS
Notes
Non Small Cell Lung Cancer FIRST-LINE as a s ingle agent for the treatment of p atients with metastatic NSCLC whose tumors have high P D-
L1 expression TPS ≥50%.
FIRST-LINE in combination with pemetrexed and carboplatin, for the treatment of patients with metastatic nonsquamous NSCLC.
SECOND-LINE as a s ingle agent for the treatment of patients with metastatic N SCLC whose tumors express PD- L1 (TPS ≥1%) w ith disease progression o n o r a fter platinum-containing chemotherapy.
Urothelial Carcinoma FIRST-LINE for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not
eligible for cisplatin-containing chemotherapy.
SECOND-LINE for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant
or adjuvant treatment with platinum-containing chemotherapy
Classical Hodgkin Lymphoma For the treatment of adult and pediatric patients with refractory cHL, or who have relapsed after 3 or more prior
lines of therapy
Melanoma FIRST & SECOND-LINE for the treatment of patients with unresectable or metastatic melanoma
Head and Neck Squamous Cell Cancer For the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-
containing chemotherapy.
MSD ONCOLOGY Lebanon : Azar Bldg. 2nd Floor Beirut, Tel: +961 1 483300 Fax: +961 1 493300 Full prescribing information is available upon request. For further inquiries please email at:DPOC_le vant@merck.com OCT-2018-LEB-ONCO-1235645-0000
DPOC_le vant@m er ck. com OCT-2018-LEB-ONCO-1235645-0000
Reference: Keytruda Lebanon Summary of Product Characteristics July 2017 TPS: Tumor Proportion Score PD-L: Programmed death Ligand
CEOP 2017 would like to thank the below sponsorsfor their contribution to the success of its annual congress
4th FLOOR, QUBIC CENTER, DAOUD AMMOUN STREET, HORSH TABET - SIN EL FILP.O BOX: 90-361 BEIRUT, LEBANON | TEL: +961 1 510880/1/2/3 | FAX Ext. 121EMAIL: INFOMED@INFOMEDWEB.COM | WEB: WWW.INFOMEDWEB.COM
Organised by: